LBI-1103

THERAPEUTIC AREA

SOLID TUMOR CANCER

LBI-1103

Indications:
Prostate, Breast, Lung, Head & Neck, Ovarian, Stomach Cancer
REGULATORY PATHWAY

New NDA

TARGET INDICATION

Advanced first in class immediate release second generation taxane based chemotherapy. Incorporate drug resistance & targeting sensitizers

CURRENT DEVELOPMENT STATUS

Pre-clinical formulation and batches complete, MTD animal testing in progress, optimizing dosing schedules. New immediate release patent filed in April 2019. Active pre-clinical development

NEXT DEVELOPMENT PHASE

Efficacy xenograft models, human tumors in animals. Pick best of 3 Solid Tumor Drug Candidates and perform pre-clinical development and file IND with FDA

TIME TO HUMAN BENEFIT

Human trials beginning in 1.25 years

IMMEDIATE FUNDING REQUIRED?

Yes, please inquire